An interim analysis of 61 sufferers with UC in this study indicated that durvalumab was well tolerated and associated with antitumor activity, particularly in patients with PD-L1-high disease (25% of tumor cells [TCs] or tumor-infiltrating immune cells expressing PD-L1), resulting in its breakthrough therapy designation by the US Food and Drug Administration (FDA)

An interim analysis of 61 sufferers with UC in this study indicated that durvalumab was well tolerated and associated with antitumor activity, particularly in patients…